MedTrace Logo

The Use of Teriparatide as an Adjunctive Therapy for the Treatment of Jones Fractures

NCT01173081 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2012-06-05

No results posted yet for this study

Summary

This randomized, placebo-controlled study will evaluate the effectiveness of the adjunctive use of teriparatide for the healing of Jones fractures.

Conditions

  • Fractures

Interventions

DRUG

Teriparatide

20mcg once daily for 16 weeks or until study endpoint is achieved.

DRUG

Placebo

matching dose of 20mcg of placebo once daily for 16 weeks or until study endpoint is achieved

Sponsors & Collaborators

Principal Investigators

  • Peter H. Edwards, Jr., MD · Ohio Orthopedic Center of Excellence

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01173081 on ClinicalTrials.gov